Home > Oncology > ASCO 2021 > Gastrointestinal Cancers > Trastuzumab-deruxtecan showed promising activity in patients with HER2-expressing mCRC

Trastuzumab-deruxtecan showed promising activity in patients with HER2-expressing mCRC

Presented By
Dr Takayuki Yoshino, National Cancer Center Hospital East, Japan
Conference
ASCO 2021
Trial
Phase 2, DESTINY-CRC01
In the phase 2, open-label DESTINY-CRC01 trial, treatment of patients with HER2-expressing metastatic colorectal cancer (mCRC) with trastuzumab-deruxtecan (T-DXd) showed promising activity and durability, as well as a manageable safety profile. Of all patients with mCRC, less than 5% have a HER2-expressing tumour [1]. Currently, no approved HER2-targeted therapies exist for mCRC. T-DXd is an antibody-drug conjugate of a humanised anti-HER2 antibody bound to a topoisomerase I inhibitor by a cleavable linker. The previously published primary results of the DESTINY-CRC01 trial (NCT03384940) demonstrated anti-tumour activity of T-DXd in patients with HER2-expressing mCRC [2]. Dr Takayuki Yoshino (National Cancer Center Hospital East, Japan) presented updated results [3]. Enrolled were 86 patients with RAS wildtype mCRC that progressed in 2 or m...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on